TargetMol

AUNP-12 acetate

Product Code:
 
TAR-TP1076L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TP1076L-1mg1mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1076L-5mg5mg£332.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1076L-10mg10mg£463.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1076L-25mg25mg£711.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1076L-50mg50mg£946.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1076L-100mg100mg£1,259.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition to immune activation and antitumor activity.
CAS:
0
Formula:
C144H230N40O50
Molecular Weight:
3321.61
Pathway:
Apoptosis; Immunology/Inflammation; Cell Cycle/Checkpoint
Purity:
0.98
SMILES:
O=C([C@@](C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])([H])N([H])C([C@](C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(N([H])[H])=O)([H])N([H])C([C@@]([C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(O[H])=O)([H])N([H])N([H])[H])=O)=O)=O)=O)=O)N1[C@@](C(N([H])[C@](C(C([C@@](C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(N([H])[H])=O)([H])N([H])C([C@@]([C@@](C([H])([H])[H])([H])O[H])([H])N([H])C([C@@](C(C([H])([H])[H])([H])C([H])([H])[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C([H])([H])N([H])/C(N([H])[H])=N/[H])([H])N([H])C([C@@](C([H])([H])C2=C([H])C([H])=C([H])C([H])=C2[H])([H])N([H])C(C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])N([H])[C@@](C(N([H])[C@](C([H])([H])O[H])([H])C(N([H])[C@@](C(N([H])[C@](C([H])([H])O[H])([H])C(N([H])[C@@](C(N([H])[C@@](C(N([H])[C@@](C([H])=O)([H])C([H])([H])O[H])=O)([H])C([H])([H])C(N([H])[H])=O)=O)([H])[C@@](C([H])([H])[H])([H])O[H])=O)=O)([H])C([H])([H])C([H])([H])C(O[H])=O)=O)=O)([H])C([H])([H])C3=C([H])C([H])=C([H])C([H])=C3[H])([H])N([H])C([C@@](C([H])([H])C4=C([H])C([H])=C([H])C([H])=C4[H])([H])N([H])C([C@@](C([H])([H])O[H])([H])N([H])C([C@@](C([H])([H])C([H])([H])C(O[H])=O)([H])N([H])C([C@@](C([H])([H])O[H])([H])N([H])C([C@@]([C@@](C([H])([H])[H])([H])O[H])([H])N([H])C([C@@](C([H])([H])C(N([H])[H])=O)([H])N([H])C([C@@](C([H])([H])O[H])([H])N([H])[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)([H])C([H])([H])[H])=O)([H])C([H])([H])C([H])([H])C1([H])[H].CC(O)=O
Target:
PD-1/PD-L1

References

Pottayil G Sasikumar, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.